METTL3 and colorectal carcinoma: Additionally, METTL3-mediated m6A mechanism contributes to promoting M2-associated therapeutic resistance, such as oxaliplatin resistance in colorectal cancer (CRC) (27) and immuno-resistance in lung adenocarcinoma (LUAD) (33).